Patents by Inventor Mauro Corsi

Mauro Corsi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of a p38 kinase inhibitor for treating psychiatric disorders
    Patent number: 7989479
    Abstract: The use of 6-(S-Cyclopropylcarbamoyl-S-fluoro-2-methyl-phenyl)-N-(2,2-dimethylproyl)-nicotinamide, which is known in the art as a p38 kinase inhibitor in the treatment or prophlaxis of one or more psychiatric disorders.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: August 2, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Mauro Corsi, Isidore Faiferman, Emilio Merlo Pich, Emiliangelo Ratti, Paul Bryan Wren
  • Novel Compounds
    Publication number: 20100144755
    Abstract: Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use use in therapy as CSBP/RK/p38 kinase inhibitors.
    Type: Application
    Filed: June 15, 2007
    Publication date: June 10, 2010
    Applicant: Glaxo Group Limited
    Inventors: Mauro Corsi, Isidore Faiferman, Emilio Merlo-Pich, Emiliangelo Ratti, Paul Bryan Wren
  • "NOVEL COMPOUNDS"
    Publication number: 20100069409
    Abstract: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, and 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(M)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.
    Type: Application
    Filed: June 15, 2007
    Publication date: March 18, 2010
    Applicant: GLAXO GROUP LIMITED
    Inventors: Mauro Corsi, Isidore Faiferman, Emilio Merlo-Pich, Emiliangelo Ratti, Paul Bryan Wren
  • Use of a p38 Kinase Inhibitor for Treating Psychiatric Disorders
    Publication number: 20100016377
    Abstract: The use of 6-(S-Cyclopropylcarbamoyl-S-fluoro-2-methyl-phenyl)-N-(2,2-dimethylproyl)-nicotinamide, which is known in the art as a p38 kinase inhibitor in the treatment or prophlaxis of one or more psychiatric disorders.
    Type: Application
    Filed: June 13, 2007
    Publication date: January 21, 2010
    Inventors: Mauro Corsi, Isidore Faiferman, Emilio Merlo Pich, Emiliangelo Ratti, Paul Bryan Wren
  • NOVEL COMPOUNDS
    Publication number: 20090318424
    Abstract: Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.
    Type: Application
    Filed: June 15, 2007
    Publication date: December 24, 2009
    Inventors: Mauro Corsi, Isidore Faiferman, Emilio Merlo-Pich, Emiliangelo Ratti, Paul Bryan Wren
  • Combinations comprising paroxetine and 2- (s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid [1- (r)- (3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide for treatment of depression and/or anxiety
    Publication number: 20060241124
    Abstract: The present invention relates to therapeutic combinations comprising paroxetine or physiologically acceptable salts or solvates thereof and 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically acceptable salts or solvates thereof, to pharmaceutical compositions containing said combinations and their use in the treatment of depression and/or anxiety.
    Type: Application
    Filed: April 16, 2004
    Publication date: October 26, 2006
    Inventors: Renzo Carletti, Mauro Corsi, Sergio Melotto
  • Combinations of paroxetine and 4- (s) - (4-acetyl-piperazin-1-yl) -2- (r)- (4-fluoro-2-methyl- phenyl -piperidine-1-carboxylic acid [1- (r) (3,5-bis-trifluoromethyl-phenyl) -ethyl] methylamide for treatment of depression and / or anxiety
    Publication number: 20060217395
    Abstract: The present invention relates to therapeutic combinations comprising paroxetine or physiologically acceptable salts or solvates thereof and 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically acceptable salts or solvates thereof, to pharmaceutical compositions containing said combinations and their use in the treatment of depression and/or anxiety.
    Type: Application
    Filed: April 16, 2004
    Publication date: September 28, 2006
    Inventors: Renzo Carletti, Mauro Corsi, Sergio Melotto
  • Chemical compounds
    Patent number: 6951861
    Abstract: The invention relates to piperazine derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to their medical use. The novel compounds are antagonists of tachykinins, including substance P and other neurokinins.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: October 4, 2005
    Assignee: SmithKline Beechan Corporation
    Inventors: Giuseppe Alvaro, Romano Di Fabio, Riccardo Giovannini, Giuseppe Guercio, Yves St-Denis, Antonella Ursini, Mauro Corsi, Sergio Melotto
  • Metabotropic glutamate receptor antagonists for treating tolerance and dependency
    Publication number: 20030195139
    Abstract: An antagonist of the metabotropic glutamate receptor 5 (mGluR5) is useful in tolerance or dependence therapy. Such an antagonist can therefore be used in the treatment of substance tolerance or dependence, bulimia nervosa, anorexia nervosa, gambling dependence, sex dependence or obsessive compulsive disorders.
    Type: Application
    Filed: April 14, 2003
    Publication date: October 16, 2003
    Inventors: Mauro Corsi, Francois Conquet
  • 1,5-benzodiazepine derivatives
    Patent number: 5716953
    Abstract: Compounds of formula (I) ##STR1## wherein the substituents are defined in the specification are antagonists of gastrin and CCK.
    Type: Grant
    Filed: March 22, 1996
    Date of Patent: February 10, 1998
    Assignee: Glaxo Wellcome S.p.A.
    Inventors: Daniele Donati, Antonella Ursini, Mauro Corsi